

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human BTNL8 in direct ELISA
Source	Monoclonal Mouse IgG _{2B} Clone # 1062028
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Synthetic peptide Fc-cleaved human BTNL8
Conjugate	Alexa Fluor 350 Excitation Wavelength: 346 nm Emission Wavelength: 442 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide
*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.	

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot	Optimal dilution of this antibody should be experimentally determined.
Immunohistochemistry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Butyrophilin-like 8 (BTNL8) is a member of the BTN/MOG Ig-superfamily and functions as a negative regulator of immune cell activation (1). Human BTNL8 is a 500 amino acid (aa) type I transmembrane glycoprotein that contains a signal peptide followed by an extracellular domain (ECD), a transmembrane region and a short cytoplasmic domain (2). The ECD of human BTNL8 shares 88% sequence identity with the ECD of mouse BTNL8. BTNL8 has two alternatively spliced forms: B7-like and BTN-like. Both isoforms of BTNL8 are expressed in a range of human tissues (3). The complete immunological function of BTNL molecules is only beginning to emerge. BTNL8 has been shown to be important in initiation of primary immune responses, suggesting a role in priming of naïve T lymphocytes (3). Down-regulation of BTNL8 mRNA levels has been associated with ulcerative colitis and colon cancer (4). BTNL8 are expressed in colon, lung, testis and neutrophils, and its expression is significantly decreased in ulcerative colitis, colonic tumors as compared to unaffected tissue (4). Soluble BTNL8-Fc fusion protein binds to resting, but not activated T cells. *In vitro*, BTNL8 co-stimulates T cell proliferation and cytokine production. *In vivo* injections of BTNL8-Fc significantly increases production of Ag-specific IgG during the primary but not the secondary immune response (3).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc., and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.